Nuclear Medicine and Biology
Volume 33, Issue 6 , Pages 773-783 , August 2006

A novel 125I-labeled daunorubicin derivative for radionuclide-based cancer therapy

  • Ludger M. Ickenstein

      Affiliations

    • Department of Physical and Analytical Chemistry, Uppsala University, P.O. Box 579, 75121 Uppsala, Sweden
    • ,
  • Katarina Edwards

      Affiliations

    • Department of Physical and Analytical Chemistry, Uppsala University, P.O. Box 579, 75121 Uppsala, Sweden
    • ,
  • Stefan Sjöberg

      Affiliations

    • Department of Biochemistry and Organic Chemistry, Uppsala University, P.O. Box 576, 75123 Uppsala, Sweden
    • ,
  • Jörgen Carlsson

      Affiliations

    • Rudbeck Laboratory, Division of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Uppsala University, 75185 Uppsala, Sweden
    • ,
  • Lars Gedda

      Affiliations

    • Rudbeck Laboratory, Division of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Uppsala University, 75185 Uppsala, Sweden
    • Rudbeck Laboratory, Division of Experimental Urology, Department of Surgery, Uppsala University, 75185 Uppsala, Sweden
    • Corresponding Author InformationCorresponding author. Rudbeck Laboratory, Division of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Uppsala University, 75185 Uppsala, Sweden. Tel.: +46 18 4713431; fax: +46 18 4713432.

Received 24 March 2006 ,Revised 19 May 2006 ,Accepted 1 June 2006.

References 

  1. Gaze MN. The current status of targeted radiotherapy in clinical practice. Phys Med Biol. 1996;41:1895–1903
  2. Order SE. Systemic radiotherapy — the new frontier. Int J Radiat Oncol Biol Phys. 1990;18:981–992
  3. Najean Y, Triebel F, Dresch C. P-32 therapy of polycythemia: a review and reappraisal. Clin Nucl Med. 1980;5:275–280
  4. Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol. 1994;31:33–40
  5. Beierwaltes WH, Nishiyama RH, Thompson NW, Copp JE, Kubo A. Survival time and “cure” in papillary and follicular thyroid carcinoma with distant metastases: statistics following University of Michigan therapy. J Nucl Med. 1982;23:561–568
  6. Oriuchi N, Higuchi T, Hanaoka H, Iida Y, Endo K. Current status of cancer therapy with radiolabeled monoclonal antibody. Ann Nucl Med. 2005;19:355–365
  7. Coakham HB, Kemshead JT. Treatment of neoplastic meningitis by targeted radiation using (131)I-radiolabelled monoclonal antibodies. Results of responses and long term follow-up in 40 patients. J Neuro-Oncol. 1998;38:225–232
  8. Kassis AI. Cancer therapy with Auger electrons: are we almost there?. J Nucl Med. 2003;44:1479–1481
  9. Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. J Nucl Med. 2005;46(Suppl. 1):4S–12S
  10. Martin RF, Haseltine WA. Range of radiochemical damage to DNA with decay of iodine-125. Science. 1981;213:896–898
  11. Hofer KG, Harris CR, Smith JM. Radiotoxicity of intracellular 67GA, 125I and 3H. Nuclear versus cytoplasmic radiation effects in murine L1210 leukaemia. Int J Radiat Biol Relat Stud Phys Chem Med. 1975;28:225–241
  12. O'Donoghue JA, Wheldon TE. Targeted radiotherapy using Auger electron emitters. Phys Med Biol. 1996;41:1973–1992
  13. Chabner BA, Meyers CE. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer: principles and practice of oncology. Philadelphia: J.B. Lippincott Co.; 1982;p. 156–197
  14. CP Association . Compendium of pharmaceuticals and specialities. vol. 13. Toronto: CK Productions; 1995;
  15. Blum RH, Carter SK. Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med. 1974;80:249–259
  16. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharm Ther. 1990;47:219–231
  17. Ghirmai S, Mume E, Tolmachev V, Sjoberg S. Synthesis and radioiodination of some daunorubicin and doxorubicin derivatives. Carbohydr Res. 2005;340:15–24
  18. Johansson E, Engvall C, Arfvidsson M, Lundahl P, Edwards K. Development and initial evaluation of PEG-stabilized bilayer disks as novel model membranes. Biophys Chem. 2005;113:183–192
  19. Beigi F, Yang Q, Lundahl P. Immobilized-liposome chromatographic analysis of drug partitioning into lipid bilayers. J Chromatogr A. 1995;704:315–321
  20. Bartlett GR. Phosphorus assay in column chromatography. J Biol Chem. 1959;234:466–468
  21. Blake A, Peacocke AR. The interaction of aminocridines with nucleic acids. Biopolymers. 1968;6:1225–1253
  22. Scatchard G. The attractions of proteins for small molecules and ions. Ann N Y Acad Sci. 1949;51:660–672
  23. McGhee JD, von Hippel PH. Theoretical aspects of DNA–protein interactions: co-operative and non-co-operative binding of large ligands to a one-dimensional homogeneous lattice. J Mol Biol. 1974;86:469–489
  24. Westermark B, Magnusson A, Heldin CH. Effect of epidermal growth factor on membrane motility and cell locomotion in cultures of human clonal glioma cells. J Neurosci Res. 1982;8:491–507
  25. Blöcher D. In chef electrophoresis a linear induction of dsb corresponds to a nonlinear fraction of extracted DNA with dose. Int J Radiat Biol. 1990;57:7–12
  26. Kullberg EB, Stenerlow B, Ghirmai S, Lundqvist H, Malmstrom PU, Orlova A, et al. An aminoacridine derivative for radionuclide therapy: DNA binding properties studied in a novel cell-free in vitro assay. Int J Oncol. 2005;27:1355–1360
  27. Chaires JB, Herrera JE, Waring MJ. Preferential binding of daunomycin to 5′ ATCG and 5′ ATGC sequences revealed by footprinting titration experiments. Biochemistry. 1990;29:6145–6153
  28. Wang AH, Ughetto G, Quigley GJ, Rich A. Interactions between an anthracycline antibiotic and DNA: molecular structure of daunomycin complexed to d(CPGPTPAPCPG) at 1.2-A resolution. Biochemistry. 1987;26:1152–1163
  29. Chaires JB, Dattagupta N, Crothers DM. Studies on interaction of anthracycline antibiotics and deoxyribonucleic acid: equilibrium binding studies on interaction of daunomycin with deoxyribonucleic acid. Biochemistry. 1982;21:3933–3940
  30. Messori L, Temperini C, Piccioli F, Animati F, Di Bugno C, Orioli P. Solution chemistry and DNA binding properties of men 10755, a novel disaccharide analogue of doxorubicin. Bioorg Med Chem. 2001;9:1815–1825
  31. Anderson AB, Xiong G, Arriaga EA. Doxorubicin accumulation in individually electrophoresed organelles. J Am Chem Soc. 2004;126:9168–9169
  32. Chen Y, Walsh RJ, Arriaga EA. Selective determination of the doxorubicin content of individual acidic organelles in impure subcellular fractions. Anal Chem. 2005;77:2281–2287
  33. Lobachevsky PN, Martin RF. Iodine-125 decay in a synthetic oligodeoxynucleotide: I. Fragment size distribution and evaluation of breakage probability. Radiat Res. 2000;153:263–270
  34. Lobachevsky PN, Martin RF. Iodine-125 decay in a synthetic oligodeoxynucleotide: II. The role of Auger electron irradiation compared to charge neutralization in DNA breakage. Radiat Res. 2000;153:271–278
  35. Kassis AI, Fayad F, Kinsey BM, Sastry KS, Adelstein SJ. Radiotoxicity of an 125I-labeled DNA intercalator in mammalian cells. Radiat Res. 1989;118:283–294
  36. Elmroth K, Stenerlow B. DNA-incorporated 125I induces more than one double-strand break per decay in mammalian cells. Radiat Res. 2005;163:369–373
  37. Kassis AI, Fayad F, Kinsey BM, Sastry KS, Taube RA, Adelstein SJ. Radiotoxicity of 125I in mammalian cells. Radiat Res. 1987;111:305–318

PII: S0969-8051(06)00103-X

doi: 10.1016/j.nucmedbio.2006.06.002

Nuclear Medicine and Biology
Volume 33, Issue 6 , Pages 773-783 , August 2006

Article Tools

* Image Usage & Resolution